Kelleni MT. Kelleni’s protocol incorporating non-steroidal anti-inflammatory drugs and nitazoxanide to early manage dengue virus disease: An antiviral silver bullet. World J Clin Cases 2025; 13(28): 108181 [DOI: 10.12998/wjcc.v13.i28.108181]
Corresponding Author of This Article
Mina Thabet Kelleni, MD, PhD, Assistant Professor, Department of Pharmacology, College of Medicine, Minia University, Main Road Shalaby Land, Minya 61519, Egypt. mina.kelleni@mu.edu.eg
Research Domain of This Article
Infectious Diseases
Article-Type of This Article
Field of Vision
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Kelleni’s protocol incorporating non-steroidal anti-inflammatory drugs and nitazoxanide to early manage dengue virus disease: An antiviral silver bullet
Mina Thabet Kelleni
Mina Thabet Kelleni, Department of Pharmacology, College of Medicine, Minia University, Minya 61519, Egypt
Author contributions: Kelleni MT wrote the article.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Mina Thabet Kelleni, MD, PhD, Assistant Professor, Department of Pharmacology, College of Medicine, Minia University, Main Road Shalaby Land, Minya 61519, Egypt. mina.kelleni@mu.edu.eg
Received: April 9, 2025 Revised: May 18, 2025 Accepted: July 7, 2025 Published online: October 6, 2025 Processing time: 122 Days and 9.2 Hours
Core Tip
Core Tip: Dengue virus disease (DVD) is estimated to affect up to 400 million people globally every year. The World Health Organization considers it the fastest growing mosquito-borne infection, and recently the infection has surpassed its historic transmission area. Unfortunately, there is no approved specific antiviral therapy to manage it. In this article, we argue that non-steroidal anti-inflammatory drugs and Kelleni's antiviral protocol could be easily repurposed to manage early DVD and prevent its progression to dengue hemorrhagic fever and death, as it has done with severe acute respiratory syndrome coronavirus 2 and other viruses. Kelleni's protocol has proven to be life-saving for patients of all ages in real-world practice, and it could be seen as an ideal empiric broad-spectrum antiviral Holy Grail that is much needed in our clinical practice.
